To analyze local therapy options for mild and moderate-severe hidradenitis suppurativa (HS) and their significance in overall management.
Key Findings:
Antiseptics and keratolytics are preferred over prolonged topical antibiotics to mitigate antimicrobial resistance, which is crucial for long-term management.
Topical 15% resorcinol shows meaningful efficacy as an alternative to clindamycin for mild-to-moderate HS, potentially reducing reliance on antibiotics.
Intralesional corticosteroids and botulinum toxin (BTX) can be beneficial in selected patients, offering tailored treatment options.
Topical Janus kinase inhibitors (JAK-I) are emerging as a therapeutic option but require further validation to establish their role in HS management.
Patient-reported outcome measures (PROMs) are crucial for assessing symptom relief from local therapies, providing insights that complement clinician-reported outcomes.
Interpretation:
Local therapies are essential in managing HS, particularly for mild cases and as adjuncts in more severe cases, with various options available that require careful consideration of efficacy, resistance, and implementation challenges.
Limitations:
Limited evidence for specific antiseptic agents in HS treatment, which may affect clinical decision-making.
The review is based on previously conducted studies without new human or animal data, limiting the novelty of findings.
Conclusion:
Local therapies remain a cornerstone in HS management, necessitating a combination of strategies tailored to individual patient needs and emphasizing the importance of personalized treatment.
